All Blogs

Sep 01, 2020

Nestle acquires peanut allergy treatment with USD 2 Billion Aimmune buyout Nestle has announced a definitive agreement to extend its acquisition of Aimmune Therapeutics. Nestle will pay an additional amount of USD 2 Billion to buy the remaining shares of Aimmune. With the acquisition, Nestle will gain Aimmune's ...

Aug 31, 2020

The current  Rosacea Pipeline therapies include FMX103 (Foamix Pharmaceuticals), Epsolay (Sol-Gel Technologies), ACU-D1 (Accuitis), HY01 (Hovione Scientia Limited), AFX4031 (Afecta Pharmaceuticals), AOB103 (AOBiome), and others. The therapies intend to address the unmet needs in the Rosacea treatment market. Awa...

Aug 28, 2020

As per DelveInsight, the Dravet syndrome market size was estimated to be USD 79.1 Million in 2017, which is expected to increase at a significant CAGR during the study period (2017–2030) owing to rich Dravet syndrome pipeline, increasing incidence, and heightened R&D. Dravet Syndrome, earlier known as sever...

Aug 27, 2020

Moderna's COVID-19 vaccine triggers an immune response in older adults Moderna showed robust phase 1 results for its COVID-19 vaccine in adults up to 55 last month. It is now following up with data from a small group of older adults, and they look positive. The phase 1 study that is being run by the National ...

Aug 26, 2020

Health care or medical care is very important for health, but it can't be the only criteria for determining health. In 1948, the WHO defined Health as a state of complete physical, mental and social well-being and not merely the absence of disease or infirmity. The definition is relevant however it didn’t address v...

Aug 25, 2020

Novartis’s Spartalizumab Combo Fails To Meet The Primary Goal In The Melanoma Trial  Novartis recently declared the results of its Phase III COMBI-I trial evaluating its experimental checkpoint inhibitor spartalizumab in combination with Tafinlar (dabrafenib) and Mekinist (trametinib) for patients, previous...

Aug 24, 2020

The launch of the Pipeline therapies, increasing EPI prevalence shall fuel the Exocrine pancreatic insufficiency market size estimated to be approximately USD 1,695.26 Million in 2017.  A loss of acinar pancreatic cells that causes insufficient production of pancreatic enzymes in the duodenum results in Exo...

Aug 20, 2020

FDA rejects BioMarin's gene therapy and Gilead's filgotinib over concerns The FDA refused to approve BioMarin's hemophilia A gene therapy valoctocogene roxaparvovec. The U.S. regulator that had earlier told there was no requirement of an AdComm for the drug, aka, valrox, has issued a complete response (CRL) lett...

Aug 21, 2020

Interstitial Cystitis market comprises robust pipeline therapies in late and mid-stage development, which are expected to be launched shortly, such as KRP-116D (Kyorin Pharmaceutical), Certolizumab pegol/ Cimzia (UCB Pharma), LP-08 (Lipella Pharmaceuticals), GRT6010 (Grünenthal), ASP6294 (Astellas Pharma), and SI-...

Oct 08, 2025

Gastroparesis is a digestive condition in which the stomach empties food into the small intestine slower than normal. This delay can cause nausea, bloating, abdominal discomfort, and a feeling of fullness even after eating small meals. Understanding the right gastroparesis diet modification is crucial for managing ...